Imaging and Treatment of Patients with Acute Stroke: An Evidence-Based Review

References

1. 1.↵
   1. Culebras A,
   2. Kase CS,
   3. Masdeu JC,
   4. et al

   . Practice guidelines for the use of imaging in transient ischemic attacks and acute stroke: a report of the Stroke Council, American Heart Association. Stroke 1997;28:1480–97

   FREE Full Text
2. 2.↵
   1. Jacobs L,
   2. Kinkel WR,
   3. Heffner RR Jr.

   . Autopsy correlations of computerized tomography: experience with 6,000 CT scans. Neurology 1976;26:1111–18

   CrossRef
3. 3.↵
   1. Schellinger PD,
   2. Jansen O,
   3. Fiebach JB,
   4. et al

   . A standardized MRI stroke protocol: comparison with CT in hyperacute intracerebral hemorrhage. Stroke 1999;30:765–68

   Abstract/FREE Full Text
4. 4.↵
   1. Patel MR,
   2. Edelman RR,
   3. Warach S

   . Detection of hyperacute primary intraparenchymal hemorrhage by magnetic resonance imaging. Stroke 1996;27:2321–24

   Abstract/FREE Full Text
5. 5.↵
   1. Fiebach JB,
   2. Schellinger PD,
   3. Gass A,
   4. et al

   . Stroke magnetic resonance imaging is accurate in hyperacute intracerebral hemorrhage: a multicenter study on the validity of stroke imaging. Stroke 2004;35:502–06

   Abstract/FREE Full Text
6. 6.↵
   1. Kidwell CS,
   2. Chalela JA,
   3. Saver JL,
   4. et al

   . Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA 2004;292:1823–30

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Fiehler J,
   2. Albers GW,
   3. Boulanger JM,
   4. et al

   . Bleeding risk analysis in stroke imaging before thromboLysis (BRASIL): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients. Stroke 2007;38:2738–44

   Abstract/FREE Full Text
8. 8.↵
   1. Lee SH,
   2. Kang BS,
   3. Kim N,
   4. et al

   . Does microbleed predict haemorrhagic transformation after acute atherothrombotic or cardioembolic stroke? J Neurol Neurosurg Psychiatry 2008;79:913–16

   Abstract/FREE Full Text
9. 9.↵
   1. Kakuda W,
   2. Thijs VN,
   3. Lansberg MG,
   4. et al

   . Clinical importance of microbleeds in patients receiving IV thrombolysis. Neurology 2005;65:1175–8

   CrossRef
10. 10.↵
    1. Libman RB,
    2. Wirkowski E,
    3. Alvir J,
    4. et al

    . Conditions that mimic stroke in the emergency department. Implications for acute stroke trials. Arch Neurol 1995;52:1119–22

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Chernyshev OY,
    2. Martin-Schild S,
    3. Albright KC,
    4. et al

    . Safety of tPA in stroke mimics and neuroimaging-negative cerebral ischemia. Neurology 2010;74:1340–45

    CrossRef
12. 12.↵
    1. Patel SC,
    2. Levine SR,
    3. Tilley BC,
    4. et al

    . Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA 2001;286:2830–38

    CrossRefPubMedWeb of Science
13. 13.↵
    1. von Kummer R,
    2. Meyding-Lamade U,
    3. Forsting M,
    4. et al

    . Sensitivity and prognostic value of early CT in occlusion of the middle cerebral artery trunk. AJNR Am J Neuroradiol 1994;15:9–15, discussion 6–8

    Abstract/FREE Full Text
14. 14.↵
    1. Hacke W,
    2. Kaste M,
    3. Fieschi C,
    4. et al

    . Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017–25

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Larrue V,
    2. von Kummer R,
    3. del Zoppo G,
    4. et al

    . Hemorrhagic transformation in acute ischemic stroke: potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 1997;28:957–60

    Abstract/FREE Full Text
16. 16.↵
    1. Larrue V,
    2. von Kummer RR,
    3. Muller A,
    4. et al

    . Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001;32:438–41

    Abstract/FREE Full Text
17. 17.↵
    1. Barber PA,
    2. Demchuk AM,
    3. Zhang J,
    4. et al

    . Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy: ASPECTS Study Group—Alberta Stroke Programme Early CT Score. Lancet 2000;355:1670–74

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Coutts SB,
    2. Demchuk AM,
    3. Barber PA,
    4. et al

    . Interobserver variation of ASPECTS in real time. Stroke 2004;35:e103–e105

    Abstract/FREE Full Text
19. 19.↵
    1. Fiebach JB,
    2. Schellinger PD,
    3. Jansen O,
    4. et al

    . CT and diffusion-weighted MR imaging in randomized order: diffusion-weighted imaging results in higher accuracy and lower interrater variability in the diagnosis of hyperacute ischemic stroke. Stroke 2002;33:2206–10

    Abstract/FREE Full Text
20. 20.↵
    1. González RG,
    2. Schaefer PW,
    3. Buonanno FS,
    4. et al

    . Diffusion-weighted MR imaging: diagnostic accuracy in patients imaged within 6 hours of stroke symptom onset. Radiology 1999;210:155–62

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Chalela JA,
    2. Kidwell CS,
    3. Nentwich LM,
    4. et al

    . Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet 2007;369:293–98

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Kidwell CS,
    2. Alger JR,
    3. Di Salle F,
    4. et al

    . Diffusion MRI in patients with transient ischemic attacks. Stroke 1999;30:1174–80

    Abstract/FREE Full Text
23. 23.↵
    1. Ay H,
    2. Buonanno FS,
    3. Rordorf G,
    4. et al

    . Normal diffusion-weighted MRI during stroke-like deficits. Neurology 1999;52:1784–92

    CrossRef
24. 24.↵
    1. An H,
    2. Ford AL,
    3. Vo K,
    4. et al

    . Signal evolution and infarction risk for apparent diffusion coefficient lesions in acute ischemic stroke are both time- and perfusion-dependent. Stroke 2011;42:1276–81

    Abstract/FREE Full Text
25. 25.↵
    1. Neumann-Haefelin T,
    2. Wittsack HJ,
    3. Wenserski F,
    4. et al

    . Diffusion- and perfusion-weighted MRI: the DWI/PWI mismatch region in acute stroke. Stroke 1999;30:1591–97

    Abstract/FREE Full Text
26. 26.↵
    1. Schwamm LH,
    2. Koroshetz WJ,
    3. Sorensen AG,
    4. et al

    . Time course of lesion development in patients with acute stroke: serial diffusion- and hemodynamic-weighted magnetic resonance imaging. Stroke 1998;29:2268–76

    Abstract/FREE Full Text
27. 27.↵
    1. Baird AE,
    2. Benfield A,
    3. Schlaug G,
    4. et al

    . Enlargement of human cerebral ischemic lesion volumes measured by diffusion-weighted magnetic resonance imaging. Ann Neurol 1997;41:581–89

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Hacke W,
    2. Albers G,
    3. Al-Rawi Y,
    4. et al

    . The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66–73

    Abstract/FREE Full Text
29. 29.↵
    1. Furlan AJ,
    2. Eyding D,
    3. Albers GW,
    4. et al

    . Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006;37:1227–31

    Abstract/FREE Full Text
30. 30.↵
    1. Hacke W,
    2. Furlan AJ,
    3. Al-Rawi Y,
    4. et al

    . Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009;8:141–50

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Albers GW,
    2. Thijs VN,
    3. Wechsler L,
    4. et al

    . Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006;60:508–17

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Albers G

    . Results of DEFUSE 2: imaging endpoints. In: Proceedings of the International Stroke Conference, New Orleans, Louisiana. February 1–3, 2012
33. 33.↵
    1. Lansberg MG

    . Results of DEFUSE 2: clinical endpoints. In: Proceedings of the International Stroke Conference, New Orleans, Louisiana. February 1–3, 2012
34. 34.↵
    1. Davis SM,
    2. Donnan GA,
    3. Parsons MW,
    4. et al

    . Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008;7:299–309

    CrossRefPubMedWeb of Science
35. 35.↵
    1. Davis SM,
    2. Donnan GA,
    3. Butcher KS,
    4. et al

    . Selection of thrombolytic therapy beyond 3 h using magnetic resonance imaging. Curr Opin Neurol 2005;18:47–52

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Lee JM,
    2. Vo KD,
    3. An H,
    4. et al

    . Magnetic resonance cerebral metabolic rate of oxygen utilization in hyperacute stroke patients. Ann Neurol 2003;53:227–32

    CrossRefPubMedWeb of Science
37. 37.↵
    1. Lu H,
    2. Xu F,
    3. Grgac K,
    4. et al

    . Calibration and validation of TRUST MRI for the estimation of cerebral blood oxygenation. Magn Reson Med 2012;67:42–49

    CrossRefPubMed
38. 38.↵
    1. Read SJ,
    2. Bladin CF,
    3. Yasaka M,
    4. et al

    . How time dependent is the threshold for cerebral infarction? Stroke 1996;27:1918–20

    PubMed
39. 39.↵
    1. Butcher K,
    2. Parsons M,
    3. Baird T,
    4. et al

    . Perfusion thresholds in acute stroke thrombolysis. Stroke 2003;34:2159–64

    Abstract/FREE Full Text
40. 40.↵
    1. Wintermark M,
    2. Flanders AE,
    3. Velthuis B,
    4. et al

    . Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. Stroke 2006;37:979–85

    Abstract/FREE Full Text
41. 41.↵
    1. Mayer TE,
    2. Hamann GF,
    3. Baranczyk J,
    4. et al

    . Dynamic CT perfusion imaging of acute stroke. AJNR Am J Neuroradiol 2000;21:1441–49

    Abstract/FREE Full Text
42. 42.↵
    1. Bivard A,
    2. McElduff P,
    3. Spratt N,
    4. et al

    . Defining the extent of irreversible brain ischemia using perfusion computed tomography. Cerebrovasc Dis 2011;31:238–45

    CrossRefPubMed
43. 43.↵
    1. Tan JC,
    2. Dillon WP,
    3. Liu S,
    4. et al

    . Systematic comparison of perfusion-CT and CT-angiography in acute stroke patients. Ann Neurol 2007;61:533–43

    CrossRefPubMedWeb of Science
44. 44.↵
    1. Parsons M,
    2. Spratt N,
    3. Bivard A,
    4. et al

    . A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 2012;366:1099–107

    CrossRefPubMedWeb of Science
45. 45.↵
    1. Hirai T,
    2. Korogi Y,
    3. Ono K,
    4. et al

    . Prospective evaluation of suspected stenoocclusive disease of the intracranial artery: combined MR angiography and CT angiography compared with digital subtraction angiography. AJNR Am J Neuroradiol 2002;23:93–101

    Abstract/FREE Full Text
46. 46.↵
    1. Katz DA,
    2. Marks MP,
    3. Napel SA,
    4. et al

    . Circle of Willis: evaluation with spiral CT angiography, MR angiography, and conventional angiography. Radiology 1995;195:445–49

    PubMedWeb of Science
47. 47.↵
    1. Nguyen-Huynh MN,
    2. Wintermark M,
    3. English J,
    4. et al

    . How accurate is CT angiography in evaluating intracranial atherosclerotic disease? Stroke 2008;39:1184–88

    Abstract/FREE Full Text
48. 48.↵
    1. Bash S,
    2. Villablanca JP,
    3. Jahan R,
    4. et al

    . Intracranial vascular stenosis and occlusive disease: evaluation with CT angiography, MR angiography, and digital subtraction angiography. AJNR Am J Neuroradiol 2005;26:1012–21

    Abstract/FREE Full Text
49. 49.↵
    1. Feldmann E,
    2. Wilterdink JL,
    3. Kosinski A,
    4. et al

    . The Stroke Outcomes and Neuroimaging of Intracranial Atherosclerosis (SONIA) trial. Neurology 2007;68:2099–106

    CrossRef
50. 50.↵
    Tissue plasminogen activator for acute ischemic stroke: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581–87

    CrossRefPubMedWeb of Science
51. 51.↵
    1. Adams HP Jr.,
    2. Brott TG,
    3. Furlan AJ,
    4. et al

    . Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke—a Statement for Healthcare Professionals From a Special Writing Group of the Stroke Council, American Heart Association. Circulation 1996;94:1167–74

    FREE Full Text
52. 52.↵
    1. Lansberg MG,
    2. Bluhmki E,
    3. Thijs VN

    . Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke. Stroke 2009;40:2438–41

    Abstract/FREE Full Text
53. 53.↵
    1. Wahlgren N,
    2. Ahmed N,
    3. Dávalos A,
    4. et al

    . Thrombolysis with alteplase 3–4·5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008;372:1303–09

    CrossRefPubMedWeb of Science
54. 54.↵
    1. Topakian R,
    2. Brainin M,
    3. Eckhardt R,
    4. et al.

    , for the SITS-Austria group. Thrombolytic therapy for acute stroke in Austria: data from the Safe Implementation of Thrombolysis in Stroke (SITS) register. Eur J Neurol 2011;18:306–11

    CrossRefPubMed
55. 55.↵
    1. Ahmed N,
    2. Wahlgren N,
    3. Grond M,
    4. et al.

    , for the SITS investigators. Implementation and outcome of thrombolysis with alteplase 3–4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 2010;9:866–74

    CrossRefPubMedWeb of Science
56. 56.↵
    1. Demchuk AM,
    2. Tanne D,
    3. Hill MD,
    4. et al.

    , for the Multicentre tPA Stroke Survey Group. Predictors of good outcome after intravenous tPA for acute ischemic stroke. Neurology 2001;57:474–80

    CrossRef
57. 57.↵
    1. Sekoranja L,
    2. Loulidi J,
    3. Yilmaz H,
    4. et al

    . Intravenous versus combined (intravenous and intra-arterial) thrombolysis in acute ischemic stroke: a transcranial color-coded duplex sonography–guided pilot study. Stroke 2006;37:18050–59
58. 58.↵
    1. Tomsick T,
    2. Brott T,
    3. Barsan W,
    4. et al

    . Prognostic value of the hyperdense middle cerebral artery sign and stroke scale score before ultraearly thrombolytic therapy. AJNR Am J Neuroradiol 1996;17:79–85

    Abstract
59. 59.↵
    1. Agarwal P,
    2. Kumar S,
    3. Hariharan S,
    4. et al

    . Hyperdense middle cerebral artery sign: can it be used to select intra-arterial versus intravenous thrombolysis in acute ischemic stroke? Cerebrovasc Dis 2004;17:182–90

    CrossRefPubMedWeb of Science
60. 60.↵
    1. Wolpert SM,
    2. Bruckmann H,
    3. Greenlee R,
    4. et al

    . Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator: the rt-PA Acute Stroke Study Group. AJNR Am J Neuroradiol 1993;14:3–13

    Abstract/FREE Full Text
61. 61.↵
    Generalized efficacy of t-PA for acute stroke: subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 1997;28:2119–25

    Abstract/FREE Full Text
62. 62.↵
    1. Furlan A,
    2. Higashida R,
    3. Wechsler L,
    4. et al

    . Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study—a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999;282:2003–11

    CrossRefPubMedWeb of Science
63. 63.↵
    The IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke 2004;35:904–11

    Abstract/FREE Full Text
64. 64.↵
    The IMS II Trail Investigators. The Interventional Management of Stroke (IMS) II Study. Stroke 2007;38:2127–35

    Abstract/FREE Full Text
65. 65.↵
    1. Mazighi M,
    2. Serfaty JM,
    3. Labreuche J,
    4. et al

    . Comparison of intravenous alteplase with a combined intravenous-endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study. Lancet Neurol 2009;8:802–09

    CrossRefPubMedWeb of Science
66. 66.↵
    The Penumbra Pivotal Stroke Trial Investigators. The Penumbra Pivotal Stroke Trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke 2009;40:2761–68

    Abstract/FREE Full Text
67. 67.↵
    1. Smith WS,
    2. et al

    . Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke 2008;39:1205–12

    Abstract/FREE Full Text
68. 68.↵
    1. Smith WS,
    2. Sung G,
    3. Starkman S,
    4. et al

    . Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005;36:1432–38

    Abstract/FREE Full Text
69. 69.↵
    1. Smith WS

    . Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke: results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, Part I. AJNR Am J Neuroradiol 2006;27:1177–82

    Abstract/FREE Full Text
70. 70.↵
    1. Saver JL,
    2. Jahan R,
    3. Levy EI,
    4. et al

    . Solitaire flow restoration device versus the Merci retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet 2012;380:1241–49

    CrossRefPubMedWeb of Science
71. 71.↵
    1. Nogueira RG,
    2. Lutsep HL,
    3. Gupta R,
    4. et al

    . Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet 2012;380:1231–40

    CrossRefPubMedWeb of Science